Face masks supplier United Sewing Automation Inc (USA) revealed on Wednesday that its ASTM Rated Level 3 Disposable PPE face masks produced at its new automated manufacturing facility in Mount Airy, NC is in compliance with the Berry Amendment and qualify for Department of Defense contracts following an extensive testing in an ISO 17025 accredited laboratory in the fight against COVID-9.
The US FDA, which oversees the sale and marketing of all surgical masks, requires that United Sewing must demonstrate mask performance in several critical areas: Bacterial Filtration, Particulate Filtration, Liquid Barrier Protection, Breathability and Flammability.
Based on the FDA requirement, the company's masks passed bacterial filtration efficiency of 99.62%, particulate filtration efficiency of 99.76%, fluid resistance at 160 mmHg, Class 1 flammability of 16CFR 1610, differential pressure at 4.8mm as well as achieved non-cytotoxic and non-irritating biocompatibility.
According to the company, the masks are made from high-quality, USA-sourced materials as well as feature a three-ply design with a built-in adjustable nose bridge and ear loops made of nylon and Spandex, providing a better fit than traditional disposable masks.
Eisai and Nuvation Bio report taletrectinib MAA validated by European regulator
Novo Nordisk's Awiqli once-weekly basal insulin treatment approved by US FDA
Lupin reports tentative FDA approval for Pitolisant Tablets
Clarity Pharmaceuticals signs copper-64 manufacturing agreement with Theragenics
Philips launches integrated IntraSight Plus platform to enhance coronary intervention efficiency
Hope Medicine reports first patient dosed in Phase III trial of HMI-115
Orsini chosen as single-source specialty pharmacy partner for Glaukos' Epioxa
GE HealthCare's Photonova Spectra gains FDA clearance
Futura Medical reports positive home user test results for Eroxon and Intense variant
GSK secures Japan Orphan Drug status for lung cancer ADC
Belief BioMed enters exclusive partnership with Grand Life Sciences for haemophilia A treatment
Glaukos launches Epioxa to advance incision-free treatment for keratoconus
Sanofi's venglustat receives FDA Breakthrough Therapy designation for type 3 Gaucher disease
Sentynl Therapeutics and PRG S&T enter licensing agreement for potential HGPS treatment